Using AI to predict treatment response in NKTCL
Part of Cancer, Immune system & allergy clinical trials.
This trial uses computer models (AI) to look at MRI scans or tissue samples from tumors to predict how well treatment will work for a rare type of lymphoma called NKTCL. It tests whether a new approach can help doctors personalize care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with a specific type of lymphoma called extranodal natural killer/T-cell lymphoma (NKTCL).
- You must be about to start your first treatment with a chemotherapy drug called asparaginase (alone or with radiation).
- You must have an MRI scan of your nasal area or a tissue sample (biopsy) from your tumor available for the study.
- You must be able to understand and sign a consent form agreeing to join the study.
- You cannot have had another type of cancer before. You also cannot have a serious psychiatric condition that would prevent you from giving consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
This trial tests a treatment plan for early-stage NK/T-cell lymphoma of the nose or throat. The treatment is adjusted based on how well the disease responds, aiming to be more effective and reduce side effects.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This study uses artificial intelligence to analyze PET/CT scans of people with T-NK cell lymphoma. The goal is to see if the AI can help doctors better diagnose this rare cancer, predict how well treatment will work, and forecast long-term outcomes.
This study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation therapy for newly diagnosed extranodal NK/T-cell lymphoma, a rare type of blood cancer. The goal is to see if this combination can help control the cancer better than standard treatment alone.
This trial tests whether using artificial intelligence to guide treatment after one round of chemotherapy works better than standard treatment for a type of blood cancer called LBCL. You'll receive initial chemotherapy, then be assigned to either an AI-guided treatment plan or standard chemotherapy based on how well you respond.
Hear when a new Natural Killer/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.